India's first indigenous dengue vaccine, DengiAll, developed by Panacea Biotec with ICMR support, has completed Phase III human trials. The single-shot vaccine aims to protect against all four dengue virus serotypes, showing 77-82% protection in earlier trials. Over 10,000 volunteers participated in the extensive Phase III study across India. If regulatory approval is granted based on positive interim analysis, DengiAll could significantly impact dengue prevention efforts globally.